Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — Quidel — Raymond James Human Health Innovation Conference 2021
17 slides from Quidelortho's conference presentation, Jun 21, 2021
Slide 1: Quidel Investor Presentation
Quidel Investor Presentation June 21, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future results and performance, such that our actual results
Slide 3: Quidel is a diagnostics company with multiple revenue opportunities
Quidel is a diagnostics company with multiple revenue opportunities. Favorable healthcare trends are expected to drive sustained growth at attractive margins. Quidel develops, We grow by introducing products manufactures, and sells to the market that address the following attributes: diagnostic solu
Slide 4: Pre-COVID, Quidel was committed to delivering strong performance by investing in growth and innovation
Pre-COVID, Quidel was committed to delivering strong performance by investing in growth and innovation. 2009 - Present REVENUES Over 25 FDA clearances ($, in millions) Acquired Triage and BNP Submitted over 30 510(k) $1,800 and expanded product Businesses from Alere packages to the FDA claims, 4 CLI
Slide 5: During the pandemic, Quidel leveraged competencies to develop and scale COVID-19 testing solutions
During the pandemic, Quidel fully leveraged competencies across the organization to quickly develop and scale several key COVID-19 testing solutions. Responded quickly to the pandemic: received 8 EUAs for COVID-19 diagnostics across multiple technologies: PCR, rapid antigen, and isothermal SARS assa
Slide 6: Going forward, Quidel emerges better positioned for long-term growth
Going forward, Quidel emerges better positioned for long-term growth. Launching Disruptive New Platforms • QuickVue ® launched in OTC / Retail, with potential to bring more POC tests into new market • Sofia ® Q near-term launch for professional segment POC and, longer-term, for At-Home / Retail • Sa
Slide 7: Our Strategic Objectives
Our Strategic Objectives Leverage Assets Fully: Launch and Scale Deploy Capital Wisely: Flagship Products: Sofia® installed base (70k+) QuickVue® Strengthen Supply Chain Established Global Sofia® Q Meaningfully increase Infrastructure production Savanna® Broader R&D Expertise Opportunistic M&A hsTro
Slide 8: Quidel products address growing market opportunities in POC immunoassay and molecular diagnostics
Quidel products address growing market opportunties, with sizeable opportunities within POC immunoassay and molecular diagnostics segments. Global IVD Sales Global Immunoassay Sales (w/o Covid) Global Molecular Sales (w/o Covid) ($ billions) ($ billions) ($ billions) 100 $95 25 12.5 +5% POC Self Tes
Slide 9: Post-COVID-19, we are targeting a near-term opportunity of $1.8B
Post-COVID-19, we are targeting a near-term opportunity of $1.8B. Global Quidel’s Addressable Markets Market Quidel’s near-term opportunities (in development or recently launched) $4,897 $1,852 Market Size Estimated Platform Product Geography (in millions) Addressable Strep 98 US $170-250 100% Vitam
Slide 10: Moving forward, Quidel's diagnostic portfolio will drive further growth
Moving forward, Quidel’s diagnostic portfolio will drive further growth. Quidel Core Non-COVID Business Short-term Growth Trend 1,400,000 • Exited Q1 21 with Sofia install base @ 70,000 creating a larger customer base for respiratory menu • Expand Sofia menu, Gastrointestinal, Strep98, others 1,200,
Slide 11: Over the next 5 years we expect to maintain our position within existing market segments
Over the next 5 years we expect to maintain our position within existing market segments while using disruptive technologies to grow into new ones. More convenient and impactful care Other Decentralized Reference Labs Hospital Labs Clinics Locations Retail At-home At-home LC Q IDNs Large Small Micro
Slide 12: Disruptive technologies: QuickVue At Home and Sofia Q
Disruptive technologies: QuickVue At Home and Sofia Q provide opportunities for Quidel to further democratize POC testing beyond traditional segments, including Direct to Consumer and Retail. ● Visually read lateral flow does not require a device to interpret results ● Results are provided in 10 min
Slide 13: Disruptive technologies: Savanna MDx, Quidel's next flagship product
Disruptive technologies: Savanna® MDx – Quidel’s next flagship product. Proven robust Fast turnaround Simplicity and Instrument technologies time ease-of-use modularity • Magnetic bead based • Fast data readout by • Direct swab and liquid • Main bay drives up to 3 nucleic acid isolation unique light
Slide 14: Our Capital Structure
Our Capital Structure Debt Type Initial Date Initial Amount Balance at 04/30/2021 Convertible Bond Debt December 2014 $172.5 million $0 Term Loan Debt October 2017 $245 million $0 Revolver Debt October 2017 $10 million $0 Deferred & Contingent $88 million October 2017 $280 million ($48 million due A
Slide 15: M&A can further enable our growth strategy
M&A can further enable our growth strategy. We have three criteria against which we are constantly evaluating opportunities X X Strategic Fit Financial Fit Ability to Execute Leverages existing assets Accelerate top-line growth Integration assessment • R&D capabilities • Existing sales call points a
Slide 16: Our Goals for 2021
Our Goals for 2021 Meet production ramp targets M&A in support of Successfully develop strategic initiatives additional immunoassays Our Goals 2021 Complete T2 R&D Investment in clinical trials support of LRP growth initiatives Commercialize Savanna® 16 Copyright © 2021 Quidel Corporation. All right
Slide 17: Slide 17
Quidel — Raymond James Human Health Innovation Conference 2021 on 6ix